May 15, 2013

Onconova Announces Presentation of Oral Rigosertib Safety and Activity Data in Lower Risk Myelodysplastic Syndromes at the 2013 ASCO Annual Meeting

May 15, 2013 – NEWTOWN, PA: Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that new safety and clinical activity data from its Phase 2 ONTARGET study will be presented on Saturday, June 1 during the American Society of Clinical Oncology Annual Meeting May 31 – June 4, 2013 in Chicago, Illinois. The ONTARGET trial is designed to evaluate oral rigosertib as a single agent in transfusion-dependent lower risk myelodysplastic syndrome patients.

Details for the presentation are as follows:

Saturday, June 1, 8:00 a.m. -12:00 p.m. CT
Poster Title: Phase II study of orally administered rigosertib (ON 01910.Na) in transfusion-dependent lower risk myelodysplastic syndrome (MDS) patients (Abstract #7031)
Location: Room S405
Presented by: Dr. Azra Raza, Director, MDS Center, Columbia University Medical Center, New York, NY

About Rigosertib
Rigosertib is an inhibitor of two important cellular signaling pathways, phosphoinositide 3-kinase, or PI3K, and polo-like kinase, or PLK, both of which are frequently activated in cancer cells. Rigosertib is being developed in both oral and intravenous forms as a treatment for hematological diseases and solid tumors. Onconova recently announced reaching the enrollment goal in its randomized, controlled ONTIME Phase 3 trial for intravenous rigosertib in adult patients with myelodysplastic syndromes whose disease has failed azacitidine or decitabine therapy. Rigosertib is also being evaluated in a Phase 3 trial for first-line treatment in combination with gemcitabine for patients with metastatic pancreatic cancer who had not previously received any chemotherapy. The oral form of rigosertib is currently being studied in Phase 2 trials in patients with transfusion-dependent lower risk myelodysplastic syndromes and in patients with head and neck cancer. Rigosertib has been granted orphan drug status for MDS in both the United States and Europe as well as orphan drug status for pancreatic cancer in the United States. Rigosertib is being developed in partnership with Baxter International (commercialization rights in Europe) and SymBio Pharmaceuticals (Japan and Korea). Onconova has retained all other territories for commercialization.

About Onconova Therapeutics, Inc.
Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive proprietary chemical library and are designed to work against specific cellular pathways that promote cancer while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are in clinical trials and several candidates are in pre-clinical stages. For more information, please visit http://www.onconova.com.

Contacts:
Benjamin Hoffman
Onconova Therapeutics
267-759-3680
bhoffman@onconova.us

Media:
Chris Erdman
MacDougall Biomedical Communications
781-235-3060
chris@macbiocom.com